Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802 · View on ClinicalTrials.gov ↗
Study Summary
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zasocitinib
Study Locations (20)
Ohio
- Apex Clinical Research Center, LLC — Canton
- Wright State Physicians — Fairborn
- Apex Clinical Research Center, LLC — Mayfield Heights
California
- Exalt Clinical Research — Chula Vista
- First OC Dermatology Research Inc. — Fountain Valley
Texas
- UT Physicians Dermatology - Bellaire Station — Bellaire
- Texas Dermatology and Laser Specialists-San Antonio — San Antonio
Other
- Peking University Third Hospital — Beijing
- Huashan Hospital Fudan University — Shanghai
Florida
- Direct Helpers Medical Center — Hialeah
Illinois
- Arlington Dermatology — Rolling Meadows
South Carolina
- Medical University of South Carolina — Charleston
Wisconsin
- Medical College of Wisconsin — Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2033-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07250802
The ClinicalTrials.gov registry entry for NCT07250802 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07250802 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Ohio, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07250802 about?
NCT07250802 is a clinical study titled "A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis". The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B wi...
What is the current status of trial NCT07250802?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2025-12-04. Estimated completion is 2033-01-24.
What conditions does trial NCT07250802 study?
This clinical trial studies the following conditions: Plaque Psoriasis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07250802?
The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07250802?
This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07250802 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.